Vanda Pharmaceuticals

CompanyUnited StatesFounded 2003

Vanda Pharmaceuticals develops 4 assets, the furthest approved (tasimelteon). Mostly small molecule acting on MTNR1B, MTNR1A and TACR1; based in the United States, founded in 2003.

4
Assets
Furthest stage: Approved; 8
Trials: 3
Signals

Pipeline

tasimelteon
Activates melatonin receptors MT1 and MT2 to regulate circadian rhythms.
Approved, Small molecule, MTNR1B, MTNR1A
tradipitant
Neurokinin-1 (NK1) receptor antagonist
Approved, Small molecule, TACR1, diabetic gastroparesis (Phase 3), gastroparesis (Phase 3)
VQW-765
Activates alpha-7 nicotinic acetylcholine receptors as a partial agonist.
Phase 3, Small molecule, social anxiety disorder

1 more asset

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

Evidence behind the mechanisms5
Trials8
Deals2
Signals8
Integrity notices1
Similar companies6